{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_3205657_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"114-464-197-955-002","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10831,"type":"PATENT","title":"University of Warwick - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1694,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8280,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: Univ* AND Warwick;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1236
Search Applicants and Owners separately: Univ* AND Warwick;
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1236
- Ar is an arene moiety;
- X is halo, or a donor ligand;
- Y represents, a cyclic or bicyclic ring structure, such as a three, four, five, six, seven or eight-membered saturated or unsaturated heterocyclic ring, which may be optionally substituted at one or more positions on the ring(s) and where the dashed line represents an optional double bond;
- Z is CR', where R' may be H, CN, N3, C1-C10 alkyl or aryl;
- R is a substituted or unsubstituted cyclic or heterocyclic ring, such as a five or six membered ring, or a chain, such as a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl or C2-C10 alkyl, optionally the ring is separated from the nitrogen to which it is attached, by a spacer group, such as a C1-C4 alkyl;
- Q is an ion and is either present or absent;
- m and n are charges, independently either absent or selected from a positive or negative whole member, or solvates or prodrugs thereof, and physiologically active derivatives thereof."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable carrier thereof."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to formula (I): or a dinuclear or polynuclear form thereof, wherein
- Ar is an arene moiety;
- X is halo, or a donor ligand;
- Y represents, a cyclic or bicyclic ring structure, such as a three, four, five, six, seven or eight-membered saturated or unsaturated heterocyclic ring, which may be optionally substituted at one or more positions on the ring(s) and where the dashed line represents and an optional double bond;
- Z is CR', where R' may be H, CN, N3, C1-C10 alkyl or aryl;
- R is a substituted or unsubstituted cyclic or heterocyclic ring, such as a five or six membered ring, or a chain, such as a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl or C2-C10 alkyl ring;
- Q is an ion and is either present or absent;
- m and n are charges, independently either absent or selected from a positive or negative whole member, or solvates or prodrugs thereof, and physiologically active derivatives thereof."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to any preceding claim, wherein the Y ring structure is a saturated N-containing five or six membered ring, such as a pyridine ring, which may optionally be substituted with a C1-C4 alkyl, OH, NH2, NO2, halo, such as I, Cl, or Br, or a peptide of 2-2O amino acids in length."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to claim 4, wherein the ring is substituted with a peptide, such as an oligo-arginine peptide."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to claim 5, wherein the peptide is an oligo-arginine peptide comprising 4-9 linearly repeating arginine molecules."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to any preceding claim wherein X is I."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to any preceding claim, wherein Ar is diphenyl."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical formulation according to any preceding claim, wherein R is an unsubstituted or substituted phenyl, or C1-C4 alkyl phenyl; when substituted, the phenyl group may be substituted on one or more carbons in the ring by C1 - C4 alkyl, OH, amino or substituted amino, e.g. dialkylamino, such as dimethylamino, carboxylate or substituted carboxylate, e.g. an ester, ether or polyether, nitro, halo, or trifluoromethyl."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical composition according to any one of claims 1-3 according to formula (II) wherein the substituents Ar, Z, X and R are as defined in claim 1, or claim 7-8 and/or the pyridine ring may optionally be substituted in accordance with claims 4-6."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical composition according to any of claims 1-3 according to formula (III) wherein the substituents X and Ar are previously as defined in claim 1, and Z is CH, R1 is H, C1 - C4 alkyl, OH, amino or substituted amino, e.g. dialkylamino, such as dimethylamino, carboxylate or substituted carboxylate, e.g. an ester, ether or polyether, nitro, halo, trifluoromethyl, or could be another ring, e.g. phenyl or substituted phenyl, 5- or 6-membered heterocyclic ring; Y' is absent or is a C(R')(R\") group."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The compound or pharmaceutical composition according to claim 10, wherein Z is CH, X is I, R1 is OH, or N(CH3)2, R' and R\" is H or methyl group independently and Q is PF6 or another negatively charged counter ion."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of preparing the compounds according to any preceding claim, the method comprising providing a compound of formula [ArOsX2]2 in a first step and then reacting the compound with an imino-containing ligand, such as an iminopyridine-containing ligand in a second step to provide a compound according to formulae (I), (II) or (III)."],"number":13,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}